Table 4.
Cancers† | HR ≥ 2.00 |
HR ≥ 2.50 |
HR ≥ 3.00 |
---|---|---|---|
No. of subjects (%) | No. of subjects ( %) | No. of subjects ( %) | |
Prostate | 52 185 (28.0) | 26 091 (14.0) | 13 045 (7.0) |
Breast | 42 887(20.0) | 15 010 (7.0) | 4288 (2.0) |
Colorectal | 40 072 (10.0) | 12 024 (3.0) | 3206 (0.8) |
Lung | 400 (0.1) | 200 (0.05) | 0 (0) |
Kidney | 2404 (0.6) | 1603 (0.4) | 1202 (0.3) |
Bladder | 0 (0) | 0 (0) | 0 (0) |
Ovary | 17 152 (8.0) | 8575 (4.0) | 0 (0) |
Pancreas | 36 070 (9.0) | 16 031 (4.0) | 1202 (0.3) |
Total ‡ | 161 723 (40.4) | 74 261 (18.5) | 22 638 (5.7) |
Hazard ratios (HRs) were estimated using Cox regression and adjusted for age, birth cohort, genotyping array, top 10 principal components for ancestry, and sex (for nonsex-specific cancer only), with middle quintile (40%-60%) as reference group.
Percentage of cancer of the prostate, breast, or ovary was calculated among men and women separately.
Number of subjects who had an elevated risk of at least one site-specific cancer. Individuals who were at high risk of multiple cancers were only counted once.